Press Releases

Date Title and Summary Additional Formats
Toggle Summary Marinus Pharmaceuticals to Participate in Leerink Global Healthcare Conference
RADNOR, Pa., Feb. 9, 2015 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced it will be participating in the Leerink Global Healthcare Conference on Thursday, February...
View HTML
Toggle Summary Marinus Pharmaceuticals Initiates Clinical Trial With Ganaxolone in PCDH19 Female Pediatric Epilepsy
RADNOR, Pa., Feb. 3, 2015 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, announced that it has initiated a Phase 2 clinical trial with ganaxolone, a synthetic analog of the...
View HTML
Toggle Summary Marinus Pharmaceuticals to Present at BIO CEO & Investor Conference
RADNOR, Pa., Feb. 2, 2015 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced that Christopher M. Cashman, Chairman and Chief Executive Officer of Marinus, will present...
View HTML
Toggle Summary Marinus Pharmaceuticals to Participate in Canaccord Genuity Rare Disease Biopharma Day
RADNOR, Pa., Jan. 27, 2015 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced it will participate in the Canaccord Genuity 2015 Rare Disease, BioPharma One-on-One Day,...
View HTML
Toggle Summary Marinus Pharmaceuticals Hires Dr. Albena Patroneva as Chief Medical Officer
RADNOR, Pa., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced that it has retained Albena Patroneva, MD as Chief Medical Officer. Dr....
View HTML
Toggle Summary Marinus Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
RADNOR, Pa., Dec. 3, 2014 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced that Christopher M. Cashman, Chairman and Chief Executive Officer of Marinus, will present...
View HTML
Toggle Summary Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2014 Financial Results
RADNOR, Pa., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today provided a business update and announced its financial results for the third quarter ended...
View HTML
Toggle Summary Marinus Pharmaceuticals to Present at the Stifel Healthcare Conference
RADNOR, Pa., Nov. 11, 2014 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced that Christopher M. Cashman, Chairman and Chief Executive Officer of Marinus, will...
View HTML
Toggle Summary Marinus Pharmaceuticals, Inc. to Present at the 21st Annual BioCentury Newsmakers Conference on Friday, September 26, 2014
NEW HAVEN, Conn., Sept. 25, 2014 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced that Edward F. Smith, Vice President and Chief Financial Officer of Marinus will...
View HTML
Toggle Summary Marinus Pharmaceuticals, Inc. Announces Exercise of Over-Allotment Option in Public Offering of Common Stock
NEW HAVEN, Conn., Sept. 2, 2014 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced that the underwriters of its previously announced public offering of common stock...
View HTML